Psychotic Disorders Archives

The Psychopharmacology of Cannabis and its Impact on Mental Health – A Primer

September 25, 2018

Cannabis is the most commonly used illicit drug in the world with approximately 13 million people estimated to be cannabis dependent. [1] When reviewing epidemiological data through population surveys and cannabis dependence data, the disability-adjusted life years was shown to account for two million years…

Understanding and Managing Obesity in Mental Health: Pharmacological Approaches

September 25, 2018

To tackle obesity in our patients, we need to understand the underlying neurobiology. [2] Gut-central nervous system (CNS) communication occurs via vagal nerve afferents as well as peripheral hormones. Learn more about the gut-brain axis. CNS stimuli relating to hunger and satiety is mediated by…

Metabolic and Cardiovascular Risks with Antipsychotics – How Can Clinicians Make a Difference?

September 20, 2018

Speaker Bio: Christoph Correll, MD, is professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies in…

Anti-N-methyl-D-aspartate (NMDA) Receptor Encephalitis – A Synopsis

August 15, 2018

In anti- NMDAR encephalitis, IGG autoantibodies directed against the GluN1a subunit of the NMDA Receptor are frequently detected in patients. [3] The NMDA is an ionotropic glutamate receptor which when activated, mediate excitatory neurotransmission via passage of sodium and calcium ions through the channel. [4]…

The Impact of Medication Adverse Effects on Quality of Life in Schizophrenia

August 15, 2018

Short author bio Christoph Correll, MD, is professor of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in New York, and Medical Director of the Recognition and Prevention (RAP) program at the Zucker Hillside Hospital in New York. He completed his medical studies…

Use of Metabolically Friendly Antipsychotics; Depression & Cognition in Schizophrenia

July 6, 2018

Update on the Treatment of Schizophrenia: Phases of Illness and Treatment Goals by Prof Correll

May 28, 2018

Protected: Can Clinicians Consider Clozapine Augmentation with Lurasidone? – Prof Correll’s Insights

May 9, 2018

A Simplified Guide to Oral Antipsychotic Medications – Mechanism of Action, Side Effects and Need to Know Points

April 29, 2018

A conventional, typical or first-generation antipsychotic is defined by the ability to block dopamine (D2) receptors. They also have in, varying degrees, M1, Alpha-1 and H1 receptor blockade. Typical antipsychotics: Chlorpromazine Flupenthixol (depot) Fluphenazine (depot) Haloperidol Sulpiride Trifluoperazine How does dopamine blockade treat psychosis? Blocking…

Schizophrenia in Women – Role of Estrogen and Novel Treatments

February 26, 2018

Prof Jayashri Kulkarni, Professor of Psychiatry and Director of Monash Alfred Psychiatry Research Centre, discusses the unique aspects of schizophrenia in women. Estrogen is a gonadal hormone that can exert powerful effects in numerous regions of the brain, consequently affecting mood, cognition, and behaviour. We…

PSYCHOTIC DISORDERS